The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Biomarin Pharmaceutical Inc shares valued at $105,928 were sold by Burkhart Erin on May 20 ’25. At $59.31 per share, Burkhart Erin sold 1,786 shares. The insider’s holdings dropped to 14,173 shares worth approximately $0.82 million following the completion of this transaction.
Also, Burkhart Erin purchased 1,786 shares, netting a total of over 105,928 in proceeds.
Before that, Hubbard Cristin had sold 273 shares from its account. In a trade valued at $17,723, the EVP, Chief Commercial Officer traded Biomarin Pharmaceutical Inc shares for $64.92 each. Upon closing the transaction, the insider’s holdings decreased to 273 shares, worth approximately $1.89 million.
Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in late February. As of November 15, 2024, Wolfe Research has initiated its “an Outperform” rating for BMRN. Earlier on October 30, 2024, William Blair downgraded its rating. Their new recommendation was “a Mkt perform” for BMRN stock which previously was a “an Outperform”.
Analyzing BMRN Stock Performance
On last trading session, Biomarin Pharmaceutical Inc [NASDAQ: BMRN] plunged -1.67% to $57.68. The stock’s lowest price that day was $57.33, but it reached a high of $58.64 in the same session. During the last five days, there has been a drop of approximately -0.67%. Over the course of the year, Biomarin Pharmaceutical Inc shares have dropped approximately -35.90%. Shares of the company reached a 52-week high of $73.51 on 03/07/25 and a 52-week low of $52.93 on 04/09/25.
Support And Resistance Levels for Biomarin Pharmaceutical Inc (BMRN)
According to the 24-hour chart, there is a support level at 57.12, which, if violated, would cause prices to drop to 56.56. In the upper region, resistance lies at 58.44. The next price resistance is at 59.20. RSI (Relative Strength Index) is 47.78 on the 14-day chart, showing neutral technical sentiment.
Is Biomarin Pharmaceutical Inc subject to short interest?
Stocks of Biomarin Pharmaceutical Inc saw a sharp steep in short interest on 2025-08-15 dropping by -1.15 million shares to 4.96 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 6.11 million shares. A decline of -23.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.1 of the overall float, the days-to-cover ratio (short ratio) decline to 2.1.
Which companies own the most shares of Biomarin Pharmaceutical Inc (BMRN)?
In terms of Biomarin Pharmaceutical Inc share price expectations, FactSet research, analysts set an average price target of 104.5 in the next 12 months, up nearly 78.15% from the previous closing price of $58.66. Analysts anticipate Biomarin Pharmaceutical Inc stock to reach 114 by 2025, with the lowest price target being 95. In spite of this, 9 analysts ranked Biomarin Pharmaceutical Inc stock as Buy at the end of 2025. On October 10, 2024, Raymond James assigned a price target of “an Outperform” to the stock and resumed coverage with a $79.
